5766 related articles for article (PubMed ID: 2496047)
21. Systemic activation of macrophages by liposome-entrapped muramyl tripeptide in mice pretreated with the chemotherapeutic agent adriamycin.
Hisano G; Fidler IJ
Cancer Immunol Immunother; 1982; 14(2):61-6. PubMed ID: 6965228
[TBL] [Abstract][Full Text] [Related]
22. Lack of production of interleukin 1 by human blood monocytes activated to the antitumor state by liposome-encapsulated muramyl tripeptide.
Tandon P; Utsugi T; Sone S
Cancer Res; 1986 Oct; 46(10):5039-44. PubMed ID: 3489519
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma.
Kleinerman ES; Gano JB; Johnston DA; Benjamin RS; Jaffe N
Am J Clin Oncol; 1995 Apr; 18(2):93-9. PubMed ID: 7900714
[TBL] [Abstract][Full Text] [Related]
24. Induction of macrophage antitumor activity by acetylated low density lipoprotein containing lipophilic muramyl tripeptide.
Shaw JM; Futch WS; Schook LB
Proc Natl Acad Sci U S A; 1988 Aug; 85(16):6112-6. PubMed ID: 3413079
[TBL] [Abstract][Full Text] [Related]
25. Muramyl tripeptide phosphatidylethanolamine encapsulated in liposomes stimulates monocyte production of tumor necrosis factor and interleukin-1 in vitro.
Maeda M; Knowles RD; Kleinerman ES
Cancer Commun; 1991; 3(10-11):313-21. PubMed ID: 1722107
[TBL] [Abstract][Full Text] [Related]
26. A dried preparation of liposomes containing muramyl tripeptide phosphatidylethanolamine as a potent activator of human blood monocytes to the antitumor state.
Sone S; Utsugi T; Tandon P; Ogawara M
Cancer Immunol Immunother; 1986; 22(3):191-6. PubMed ID: 3731204
[TBL] [Abstract][Full Text] [Related]
27. Activation of tumoricidal properties in human blood monocytes by liposomes containing lipophilic muramyl tripeptide.
Kleinerman ES; Erickson KL; Schroit AJ; Fogler WE; Fidler IJ
Cancer Res; 1983 May; 43(5):2010-4. PubMed ID: 6831430
[TBL] [Abstract][Full Text] [Related]
28. Induction of nitric oxide production and tumoricidal properties in murine macrophages by a new synthetic lipopeptide JBT3002 encapsulated in liposomes.
Eue I; Kumar R; Dong Z; Killion JJ; Fidler IJ
J Immunother; 1998 Sep; 21(5):340-51. PubMed ID: 9789196
[TBL] [Abstract][Full Text] [Related]
29. Synergism between human recombinant gamma-interferon and muramyl dipeptide encapsulated in liposomes for activation of antitumor properties in human blood monocytes.
Saiki I; Sone S; Fogler WE; Kleinerman ES; Lopez-Berestein G; Fidler IJ
Cancer Res; 1985 Dec; 45(12 Pt 1):6188-93. PubMed ID: 3933823
[TBL] [Abstract][Full Text] [Related]
30. Prevention of chemotherapy- or X-irradiation-induced monocytopenia by oral administration of lipophilic muramyl tripeptide.
Killion JJ; Brown DR; Wilson MR; Lloyd MM; Fidler IJ
Oncol Res; 1994; 6(8):357-64. PubMed ID: 7894085
[TBL] [Abstract][Full Text] [Related]
31. Liposome-encapsulated muramyl tripeptide: a new biologic response modifier for the treatment of osteosarcoma.
Kleinerman ES; Maeda M; Jaffe N
Cancer Treat Res; 1993; 62():101-7. PubMed ID: 8096724
[TBL] [Abstract][Full Text] [Related]
32. Mouse interferon-gamma in liposomes: pharmacokinetics, organ-distribution, and activation of spleen and liver macrophages in vivo.
Hockertz S; Franke G; Kniep E; Lohmann-Matthes ML
J Interferon Res; 1989 Oct; 9(5):591-602. PubMed ID: 2507661
[TBL] [Abstract][Full Text] [Related]
33. Analysis of the antimetastatic effects of synthetic muramyl tripeptide (CGP 19835A) encapsulated in liposomes in combination with other immunomodulatory agents and chemotherapeutic drugs.
Bezault J; Walsh C; Tarcsay L; Frost H; Liebes L; Furmanski P
In Vivo; 1993; 7(6A):487-91. PubMed ID: 8193265
[TBL] [Abstract][Full Text] [Related]
34. Comparative interaction of free and liposome-encapsulated nor-muramyl dipeptide or muramyl tripeptide phosphatidylethanolamine (3H-labelled) with human blood monocytes.
Fogler WE; Fidler IJ
Int J Immunopharmacol; 1987; 9(2):141-50. PubMed ID: 3583507
[TBL] [Abstract][Full Text] [Related]
35. In vivo modulation of macrophage tumoricidal activity by oral administration of the liposome-encapsulated macrophage activator CGP 19835A.
Tanguay S; Bucana CD; Wilson MR; Fidler IJ; von Eschenbach AC; Killion JJ
Cancer Res; 1994 Nov; 54(22):5882-8. PubMed ID: 7954418
[TBL] [Abstract][Full Text] [Related]
36. Induction and maintenance of monocyte cytotoxicity during treatment with liposomes containing muramyl tripeptide despite tachyphylaxis to the cytokine response.
Galligioni E; Favaro D; Santarosa M; Quaia M; Spada A; Freschi A; Alberti D
Clin Cancer Res; 1995 May; 1(5):493-9. PubMed ID: 9816008
[TBL] [Abstract][Full Text] [Related]
37. Activation of macrophage cytostatic and cytotoxic activity in vitro by liposomes containing a new lipophilic muramyl peptide derivative, MDP-L-alanyl-cholesterol (MTP-CHOL).
Phillips NC; Moras ML; Chedid L; Petit JF; Tenu JP; Lederer E; Bernard JM; Lefrancier P
J Biol Response Mod; 1985 Oct; 4(5):464-74. PubMed ID: 3935756
[TBL] [Abstract][Full Text] [Related]
38. Distribution and fate of free and liposome-encapsulated [3H]nor-muramyl dipeptide and [3H]muramyl tripeptide phosphatidylethanolamine in mice.
Fogler WE; Wade R; Brundish DE; Fidler IJ
J Immunol; 1985 Aug; 135(2):1372-7. PubMed ID: 4008926
[TBL] [Abstract][Full Text] [Related]
39. Potentiating effect of muramyl dipeptide and its lipophilic analog encapsulated in liposomes on tumor cell killing by human monocytes.
Sone S; Mutsuura S; Ogawara M; Tsubura E
J Immunol; 1984 Apr; 132(4):2105-10. PubMed ID: 6699409
[TBL] [Abstract][Full Text] [Related]
40. Augmentation of NK cell activity in tissue specific sites by liposomes incorporating MTP-PE.
Talmadge JE; Schneider M; Collins M; Phillips H; Herberman RB; Wiltrout RH
J Immunol; 1985 Aug; 135(2):1477-83. PubMed ID: 4008928
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
